Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx (NASDAQ: RARE) reported an inducement grant of 20,317 restricted stock units (RSUs) to 17 newly hired non-executive officers, approved by the compensation committee and granted under the Ultragenyx Employment Inducement Plan.
The grant date was October 16, 2025 and the awards were disclosed October 24, 2025 as material inducements under Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years with 25% vesting on each anniversary, contingent on continuous employment.
Ultragenyx (NASDAQ: RARE) ha annunciato una concessione di incentivazione di 20.317 unità di azioni vincolate (RSU) a 17 nuovi dirigenti assunti non esecutivi, approvata dal comitato di compensazione e concessa ai sensi dell’Ultragenyx Employment Inducement Plan.
La data di concessione è stata il 16 ottobre 2025 e le assegnazioni sono state dichiarate il 24 ottobre 2025 come incentivi sostanziali ai sensi della Nasdaq Listing Rule 5635(c)(4). Le RSU vestono in quattro anni, con il 25% di vesting a ciascun anniversario, soggetto al mantenimento del rapporto di lavoro.
Ultragenyx (NASDAQ: RARE) informó una concesión de incentivo de 20.317 unidades de acciones restringidas (RSU) a 17 nuevos empleados no ejecutivos contratados, aprobada por el comité de compensación y otorgada conforme al Ultragenyx Employment Inducement Plan.
La fecha de concesión fue el 16 de octubre de 2025 y las adjudicaciones se divulgaron el 24 de octubre de 2025 como incentivos materiales bajo la regla de listado de Nasdaq 5635(c)(4). Las RSU se consolidan en cuatro años con un 25% de vesting en cada aniversario, sujeto a empleo continuo.
Ultragenyx (NASDAQ: RARE)은 17명의 새 채용 비상임 임원들에게 20,317개의 제한된 주식 단위(RSU)의 유인 부여를 보고했으며, 보상위원회가 승인하고 Ultragenyx Employment Inducement Plan에 따라 부여되었습니다.
부여일은 2025년 10월 16일이며, 보상 부여는 2025년 10월 24일에 나스닥 상장 규칙 5635(c)(4)에 따른 중요한 유인으로 공시되었습니다. RSU는 4년에 걸쳐 시작되며, 매년 25%의 가속 vesting가 지속적으로 고용되는 조건에서 이루어집니다.
Ultragenyx (NASDAQ: RARE) a annoncé une attribution d’incitation de 20 317 unités d’actions restreintes (RSU) à 17 nouveaux cadres non exécutifs recrutés, approuvée par le comité de rémunération et accordée dans le cadre du Ultragenyx Employment Inducement Plan.
La Date d’attribution est fixée au 16 octobre 2025 et les attributions ont été rendues publiques le 24 octobre 2025 en tant qu’incitations matérielles au titre de la règle de cotation Nasdaq 5635(c)(4). Les RSU vestent sur quatre ans avec 25% qui se vestent à chaque anniversaire, sous condition d’emploi continu.
Ultragenyx (NASDAQ: RARE) meldete eine Anreizgewährung von 20.317 RSUs (Begrenzt Aktieneinheiten) an 17 neu eingestellte nichtleitende Führungskräfte, genehmigt vom Vergütungsausschuss und im Rahmen des Ultragenyx Employment Inducement Plan gewährt.
Das Zuteilungsdatum war der 16. Oktober 2025, und die Vergütungen wurden am 24. Oktober 2025 als wesentliche Anreize gemäß Nasdaq Listing Rule 5635(c)(4) bekannt gegeben. Die RSUs vesten über vier Jahre mit 25% Vesting an jedem Jahrestag, vorbehaltlich der fortlaufenden Beschäftigung.
Ultragenyx (NASDAQ: RARE) أبلغت عن منحة حثّية قدرها 20,317 وحدة أسهم مقيدة (RSUs) لـ 17 من الموظفين الجدد غير التنفيذيين، تمت الموافقة عليها من قبل لجنة التعويض ومنحت وفقاً لـ خطة التعجيل بالعمل Ultragenyx Employment Inducement Plan.
تاريخ المنحة هو 16 أكتوبر 2025 وقد كُشفت الجوائز في 24 أكتوبر 2025 كحوافز جوهرية وفق قاعدة إدراج ناسداك 5635(c)(4). ترسخ RSUs على مدى أربعة سنوات مع تسجيل 25% في كل ذكرى، رهناً باستمرار التوظيف.
Ultragenyx (NASDAQ: RARE) 报告称向 17名新雇用的非执行官员授予了 20,317份受限股票单位（RSU）的激励性授予，获薪酬委员会批准，并根据 Ultragenyx Employment Inducement Plan 授予。
授予日期 为 2025 年 10 月 16 日，获奖在 2025 年 10 月 24 日作为根据 Nasdaq Listing Rule 5635(c)(4) 的实质性诱因披露。RSU 将在 四年内逐步解锁，在 每个周年日解锁 25%，前提是持续在职。
- None.
- None.
NOVATO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 20,317 restricted stock units of the company’s common stock to 17 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of October 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
FAQ
How many RSUs did Ultragenyx grant on October 16, 2025 under Nasdaq Rule 5635(c)(4)?
How many employees received the inducement RSUs from Ultragenyx (RARE)?
What is the vesting schedule for the Ultragenyx RSUs granted October 16, 2025?
Why did Ultragenyx disclose the grant under Nasdaq Listing Rule 5635(c)(4)?
Will Ultragenyx shareholders see immediate dilution from the 20,317 RSUs?
